A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DDIs / drug-drug interactions

[Related PubMed/MEDLINE]
Total Number of Papers: 1309
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DDIs  (>> Co-occurring Abbreviation)
Long Form:   drug-drug interactions
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2021 A Comprehensive Review of Computational Methods for Drug-drug Interaction Detection. ---
2021 A computational approach to predict multi-pathway drug-drug interactions: A case study of irinotecan, a colon cancer medication. ---
2021 A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions. CYP3A4, PBPK
2021 A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults. allo-HCT, pcon-meds, PK
2021 A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management. AEs
2021 A review of pharmacokinetic drug interactions between antimicrobial and antiseizure medications in children. ASMs, CBZ, PHT, VPA
2021 A Review of the Metabolism and Potential Drug-drug Interactions With Addictive Drugs. PWUD
2021 A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. ---
2021 A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators. OCTs, PBPK, PMAT
10  2021 Absorption, Metabolism, Distribution, and Excretion of Letermovir. HSCT, OATP, P-gp
11  2021 Advancement in predicting interactions between drugs used to treat psoriasis and its comorbidities by integrating molecular and clinical resources. AUROC
12  2021 Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs. ARAs, ASD, AUC, IR, TKI
13  2021 An International Consensus List of Potentially Clinically Significant Drug-Drug Interactions in Older People. ---
14  2021 An introduction to network analysis for studies of medication use. DPN, NA, NorPD
15  2021 Assessing Consistency of Drug-Drug Interaction-Related Information Across Various Drug Information Resources. DI
16  2021 Assessment of Potential Drug-Drug Interactions and Their Predictors in Chronic Outpatient Department of Dessie Referral Hospital, Dessie, Northeast Ethiopia. DRH
17  2021 Assessment of the Potential for Veverimer Drug-Drug Interactions. ---
18  2021 AttentionDDI: Siamese attention-based deep learning method for drug-drug interaction predictions. ---
19  2021 Automatically classifying the evidence type of drug-drug interaction research papers as a step toward computer supported evidence curation. ---
20  2021 Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization. CBD, Delta9-THC
21  2021 Case Study 5: Predicting the Drug Interaction Potential for Inhibition of CYP2C8 by Montelukast. ---
22  2021 Changing Pattern of Chemsex Drug Use Among Newly Diagnosed HIV-Positive Taiwanese from 2015 to 2020 in the Era of Treat-All Policy. ART, CDU, HIV/AIDS, STDs
23  2021 Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. CBD, CYP450
24  2021 Clinically important drug-drug interactions in patients admitted to hospital with COVID-19: drug pairs, risk factors, and management. COVID-19, pDDIs
25  2021 Co-delivery systems: hope for clinical application? ---
26  2021 Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium: an observational study. DAA, HCV
27  2021 Comparing Potential Drug-Drug Interactions in Companion Animal Medications Using Two Electronic Databases. ---
28  2021 Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region. NSAIDs
29  2021 Comparison of Clinical Importance of Drug Interactions Identified by Hospital Pharmacists and a Local Clinical Decision Support System. CDSSs
30  2021 Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase. BTK, FDA, UGT
31  2021 Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitude. COVID-19, HCQ
32  2021 Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide. BCRP, MRP4, OATP2B1, OATs, P-gp, PBPK, PK
33  2021 Current Knowledge about Providing Drug-Drug Interaction Services for Patients-A Scoping Review. CDSS
34  2021 CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients. CONF
35  2021 Cytochrome P450 3A Time-Dependent Inhibition Assays Are Too Sensitive for Identification of Drugs Causing Clinically Significant Drug-Drug Interactions: A Comparison of Human Liver Microsomes and Hepatocytes and Definition of Boundaries for Inactivation Rate Constants. hHeps, HLMs, TDI
36  2021 Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia. COVID-19
37  2021 DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions. DDIWAS, EHR
38  2021 Designing and evaluating contextualized drug-drug interaction algorithms. EHRs
39  2021 Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations. PBPK
40  2021 Differences in the Hemolytic Behavior of Two Isomers in Ophiopogon japonicus In Vitro and In Vivo and Their Risk Warnings. OP-D
41  2021 Do Inhibitory Metabolites Impact DDI Risk Assessment? Analysis of in vitro and in vivo Data from NDA Reviews Between 2013 and 2018. Cmax
42  2021 Does DDI-Predictor Help Pharmacists to Detect Drug-Drug Interactions and Resolve Medication Issues More Effectively? DDI-P, GUH, PAR, PIR
43  2021 Drug Interactions Involving 17α-Ethinylestradiol: Considerations Beyond Cytochrome P450 3A Induction and Inhibition. NMEs, OCs, UGT
44  2021 Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined in Silico Pharmacokinetic and Pharmacodynamic Modeling Approach. DZP, KOR, MD, MM-PBSA, MOR, OXY, PBPK, PD, PK
45  2021 Drug-Drug interaction extraction using a position and similarity fusion-based attention mechanism. Bi-LSTM
46  2021 Drug-Drug Interaction Predictions via Knowledge Graph and Text Embedding: Instrument Validation Study. ---
47  2021 Drug-drug interactions and inappropriate medicines impact on glycemic control and kidney function in older adults with diabetes-attending specialty care institution. T2D
48  2021 Drug-Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN® System Comprehensive Approach. CRC, DDGIs
49  2021 Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. COVID-19, PIMs, SARS-CoV-2
50  2021 Drug-Drug Interactions at Organic Cation Transporter 1. OCT1, SLC22A
51  2021 Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. pDDIs
52  2021 Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. CNS, GLE/PIB, HCV, pDAAs, SOF/VEL
53  2021 Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. DAAs, HCV
54  2021 Drug-drug interactions with OTC medicines: mind the unprescribed. OTC
55  2021 Drug-related challenges following primary total hip and knee arthroplasty. NSAID, THA or TKA
56  2021 Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data. ADRs, COVID-19
57  2021 Effect of nationwide concurrent drug utilization review program on drug-drug interactions and related health outcome. CI, DUR, ED, OR
58  2021 Effect of pharmacodynamical interaction between nutlin-3a and aspirin in the activation of p53. PID
59  2021 Epidemiology and associated factors of polypharmacy in older patients in primary care: a northern Italian cross-sectional study. PIMs
60  2021 Evaluation of a specialty hepatitis C virus telephone pharmacy service. DAAs, HCV
61  2021 Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route. BUP-XR, OUD, PBPK, PK
62  2021 Evaluation of drug-drug interactions in cancer patients treated at a university hospital in North Cyprus using two interaction databases. ---
63  2021 Evaluation of drug-drug interactions in hospitalized patients on medications for OUD. ---
64  2021 Evaluation of Normothermic Machine Perfusion of Porcine Livers as a Novel Preclinical Model to Predict Biliary Clearance and Transporter-Mediated Drug-Drug Interactions Using Statins. NMP
65  2021 Evaluation of Pharmacokinetic Drug-Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches. PBPK
66  2021 Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. ALS, PK
67  2021 Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D2/D3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters. OATP, P-gp
68  2021 Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial. AUCs, CGRP, CIs, TEAEs, tmax
69  2021 Evaluation of the use of chlorpromazine for agitation in pediatric patients. ---
70  2021 Exploration of inhibition potential of isoniazid and its metabolites towards CYP2E1 in human liver microsomes through LC-MS/MS analysis. HLM, MBI, TB
71  2021 Finding Causal Mechanistic Drug-Drug Interactions from Observational Data. ADRs
72  2021 Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US. JAK, RA
73  2021 Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B. CI
74  2021 High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction. ART, ED, PDE-5, PIs
75  2021 Identification and management of contraindicated drug-drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy. ADEs, DAAs
76  2021 Identification of human UDP-glucuronosyltransferase and sulfotransferase as responsible for the metabolism of dotinurad, a novel selective urate reabsorption inhibitor. HIC, HLC, HLMs, SULT, UGT
77  2021 Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database. ADRs
78  2021 Impact of Polypharmacy Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Older Adults. AEs, allo-HCT, CI, HCTCI, HRs, LOS, NRM, OS, PFS, PIM
79  2021 In Silico Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 Isoforms. LOOCV, PASS, PoSMNA, SAR
80  2021 In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters. BCRP, MRP, OAT1, OATP, P-gp, URAT1
81  2021 In Vitro Screening of Three Commercial Cannabis-Based Products on ATP-Binding Cassette and Solute-Carrier Transporter Function. ABC, CBD, Delta9-THC, SLC
82  2021 Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced Patients. ART, CM, PWH, SD
83  2021 Inhibition of human UDP-glucuronosyltransferase enzyme by Dabrafenib: Implications for drug-drug interactions. 4-MU, TKI, UGTs
84  2021 Integrated Random Negative Sampling and Uncertainty Sampling in Active Learning Improve Clinical Drug Safety Drug-Drug Interaction Information Retrieval. ADEs, AL, IR, LR, ML, SVM
85  2021 Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents. OAT3
86  2021 Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population. AUC, CABP, DDI, PBPK
87  2021 Medication errors in hematology-oncology ward by consultation: The role of the clinical pharmacologist. ---
88  2021 MUFFIN: Multi-Scale Feature Fusion for Drug-Drug Interaction Prediction. KG
89  2021 Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study. AF, ASMs, CYP3A4, NOACs, P-gp, TIA
90  2021 Novel method for the prediction of drug-drug Interaction based on gene expression profiles. FE, TD
91  2021 Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance. ECC, PBPK, PK
92  2021 Patient- and Prescriber-Related Factors Associated with Potentially Inappropriate Medications and Drug-Drug Interactions in Older Adults. COC, PIM
93  2021 PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. AML, AUC, IDH1, OAT3, P-gp, PK
94  2021 Pediatric Drug-Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations. ---
95  2021 Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients. ADRs, AZCERT, TdP
96  2021 Pharmacokinetic drug interactions between antiseizure medications and drugs for comorbid diseases in children with epilepsy. ASMs
97  2021 Pharmacotherapy Profiles in People with Opioid Use Disorders: Considerations for Relevant Drug-Drug Interactions with Antiviral Treatments for Hepatitis C. HCV, OST, PWID
98  2021 Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption. PBPK
99  2021 Physiologically-based Pharmacokinetic (PBPK) Modelling of Transporter Mediated Drug Absorption, Clearance and Drug-drug Interactions. PBPK
100  2021 Physiologically-based Pharmacokinetic Modeling to Evaluate In Vitro-to-In Vivo Extrapolation for Intestinal Pgp Inhibition. IVIVE, PBPK